Key result
Atorvastatin/ezetimibe is linked to ~11 percentage points higher LDL-C goal attainment versus monotherapy.
Why the study?
LDL-C goal attainment rates in Korean patients with hypercholesterolemia treated with atorvastatin/ezetimibe versus atorvastatin monotherapy were not well characterized in real-world practice.
Does atorvastatin/ezetimibe combination therapy improve LDL-C goal attainment compared to atorvastatin monotherapy in statin-naïve patients with hypercholesterolemia?
Observational (n=969)
Yes
Does atorvastatin/ezetimibe combination therapy improve LDL-C goal attainment compared to atorvastatin monotherapy in statin-naïve patients with hypercholesterolemia?
Answers are grounded in this paper and cite their sources.
In real-world clinical practice among statin-naïve Korean patients, upfront treatment with atorvastatin/ezetimibe combination significantly improved LDL-C goal attainment and lipid reductions compared to atorvastatin monotherapy.
Purpose: To investigate low-density lipoprotein cholesterol (LDL-C) goal attainment rates in patients with hypercholesterolemia treated with atorvastatin/ezetimibe or atorvastatin monotherapy. Methods: This was a multicenter, noninterventional, retrospective, chart review study of Korean patients with hypercholesterolemia who were statin-naïve and prescribed atorvastatin/ezetimibe or atorvastatin monotherapy during an observational period, from January 2014 to July 2017, and followed up for 12–18 weeks. Patients were propensity score matched to reduce treatment selection bias. Outcomes included LDL-C goal attainment rate at week 12, defined by risk groups according to Korean Society of Lipidology and Atherosclerosis guidelines; and change in lipid parameters from the index date to week 12. Results: A total of 969 patients were enrolled in the study: atorvastatin/ezetimibe, n = 349; atorvastatin monotherapy, n = 620. Following propensity matching (n = 316 in each group), respective LDL-C goal attainment rates for atorvastatin/ezetimibe and atorvastatin monotherapy groups were 86% and 75%, respectively (p = 0.0004). Atorvastatin/ezetimibe produced significantly larger reductions at week 12 in mean LDL-C (−50.3% vs −42.7%), total cholesterol (−36.8% vs −30.7%) and non-high-density lipoprotein cholesterol (non-HDL-C; −47.3% vs −39.8%) levels compared to atorvastatin monotherapy (all p < 0.0001). Conclusion: More patients achieved LDL-C goal attainment with atorvastatin/ezetimibe than with atorvastatin monotherapy, and atorvastatin/ ezetimibe was associated with significantly larger reductions in mean LDL-C, total cholesterol and non-HDL-C levels than atorvastatin monotherapy, in Korean patients with hypercholesterolemia in a real-world clinical practice.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2019) conducted an observational in Hypercholesterolemia (n=969). Atorvastatin/ezetimibe vs. Atorvastatin monotherapy was evaluated on LDL-C goal attainment rate at week 12 (p=0.0004). Atorvastatin/ezetimibe was associated with a higher LDL-C goal attainment rate at 12 weeks compared to atorvastatin monotherapy in statin-naïve patients.
Synapse has enriched 10 related papers. Consider them for comparative context: